Trends and treatment outcomes of drug resistant tuberculosis in Limpopo Province, South Africa (2011–2019): A Retrospective Study
PLOS One · 18.11.2025 · 20 (11) · e0335600
DOI: 10.1371/journal.pone.0335600 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 18.11.2025. Verfasst von Kabelo Gabriel Kaapu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Microbiology, Department of Pathology, School of Medicine, University of Limpopo, Limpopo, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug-resistant tuberculosis (DR-TB) continues to threaten TB control efforts in South Africa, particularly in resource-limited provinces such as Limpopo. This study evaluated trends in DR-TB and evaluated treatment outcomes and predictors of unfavorable outcomes from 2011 to 2019.
Methods
We conducted a retrospective cross-sectional study using data from 3,528 patients with DR-TB recorded in the Limpopo electronic registry (EDRWeb.net). Descriptive statistics characterized the demographics of the patients and the types of resistance. The associations between variables and outcomes were tested using chi-square analysis and binary logistic regression identified independent predictors of unfavorable treatment outcomes. The study period was stratified into pre-bedaquiline (BDQ) (2011–2015) and post-BDQ (2016–2019) eras to assess the impact of treatment.
Results
Rifampicin-resistant TB (RR-TB) (61.7%) and multidrug-resistant TB (MDR-TB) (32.5%) were the most common. Overall, the success of the treatment was 59.0%, increasing from 54.1% in the pre-BDQ era to 65.3% after BDQ. XDR-TB had the lowest success rate (31.3%). In multivariate analysis, male sex (aOR = 1.12; 95% CI: 1.00–1.27), HIV positivity (aOR = 1.28; 95% CI: 1.11–1.47), age ≥ 35 years (aOR = 2.01; 95% CI: 1.08–3.76), and XDR-TB (aOR = 3.05; 95% CI: 1.65–5.65) were independently associated with unfavorable outcome.
Conclusion
Treatment outcomes for DR-TB in Limpopo improved following the introduction of BDQ and shorter all-oral regimens but remain suboptimal, particularly among XDR-TB and HIV co-infected patients. Strengthening TB/HIV integration, expanding access to new drug regimens, and enhancing early diagnosis are essential to improve outcomes in rural high-burden settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Microbiology, Department of Pathology, School of Medicine, University of Limpopo, Limpopo, South Africa.
- Department of Medical Microbiology, National Health Laboratory Service, Polokwane, Limpopo, South Africa.
ORCID-Profile: Kabelo Gabriel Kaapu
Zitieren
APA
Kaapu, K. G., & Rukasha, I. (2025). Trends and treatment outcomes of drug resistant tuberculosis in Limpopo Province, South Africa (2011–2019): A Retrospective Study. PLOS One, 20(11), e0335600. https://doi.org/10.1371/journal.pone.0335600
Vancouver
Kaapu KG, Rukasha I. Trends and treatment outcomes of drug resistant tuberculosis in Limpopo Province, South Africa (2011–2019): A Retrospective Study. PLOS One. 2025;20(11):e0335600. doi:10.1371/journal.pone.0335600
BibTeX
@article{Kaapu2025,
author = {Kaapu, Kabelo Gabriel and Rukasha, Ivy},
title = {Trends and treatment outcomes of drug resistant tuberculosis in Limpopo Province, South Africa (2011–2019): A Retrospective Study},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {11},
pages = {e0335600},
doi = {10.1371/journal.pone.0335600}
}
EUVIMED